Shuntai Chen

Shuntai Chen

Auto-generated profile, based on publicly available information

Shuntai Chen

Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Gastroenterology
Verified
Journal Article
Closed access
XZXing Zhang
Xing Zhang
MLMeng Li
Meng Li
SCShuntai Chen
Shuntai Chen
JHJiaqi Hu
Jiaqi Hu
QGQiujun Guo
Qiujun Guo
宝华宝金 华
宝金 华

16 November 2016 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
QGQiujun Guo
Qiujun Guo
ZJZhichao Jin
Zhichao Jin
YYYuan Yuan
Yuan Yuan
RLRui Liu
Rui Liu
TXTao Xu
Tao Xu
BHBaojin Hua
Baojin Hua
The majority of basic and clinical studies have shown a protumor function of tumor-associated macrophages (TAMs), which represent a large proportion of matrix cells. TAMs promote tumorigenesis, and their number is related to the malignancy degree and poor prognosis of many kinds of tumors. Macrophage plasticity makes it possible to change the tumor microenvironment and remodel antitumor immunity during cancer immunotherapy. Increasing numbers of studies have revealed the effects of TAMs on the tumor microenvironment, for example, via promotion of tumor growth and tumorigenesis and through an increase in the number of cancer stem cells or via facilitation of angiogenesis, lymphangiogenesis, and metastasis. Investigators also proposed tumor-immunological treatments targeting TAMs by inhibiting TAM recruitment and differentiation, by regulating TAM polarization, and by blocking factors and pathways associated with the protumor function of TAMs. This comprehensive review presents recent research on TAMs in relation to prediction of poor outcomes, remodeling of the tumor immune microenvironment, and immunological targeted therapies.

1 January 2016 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
TXTao Xu
Tao Xu
ZJZhichao Jin
Zhichao Jin
YYYuan Yuan
Yuan Yuan
HWHuamin Wei
Huamin Wei
XXXinyao Xu
Xinyao Xu
BHBaojin Hua
Baojin Hua
Objective. To evaluate ginsenoside Rg3 combined with chemotherapy for non‐small‐cell lung cancer (NSCLC) treatment, in a meta‐analysis. Materials and Methods. We searched PubMed, EMBASE, the Cochrane Library, the China National Knowledge Infrastructure, and the VIP and Wanfang databases for eligible studies. We manually searched for printed journals and relevant textbooks. Statistical analyses were performed with Revman 5.3 and STATA 14.0 software packages. Results. Twenty studies were included. Ginsenoside Rg3 combined with chemotherapy could enhance response, improve disease control, prolong overall survival, improve patient quality of life, reduce leucocyte count decrease due to chemotherapy, reduce vascular endothelial growth factor expression in peripheral blood, and increase CD4/CD8 T cell ratio. Conclusion. Ginsenoside Rg3 combined with chemotherapy may enhance short‐term efficacy and overall survival, alleviate treatment‐induced side effects, reduce vascular endothelial growth factor expression, increase CD4/CD8 T cell ratio, and serve as a potential therapeutic regimen for NSCLC. However, considering the limitations, the conclusion should be interpreted carefully, and these results need to be confirmed by more high‐quality trials.

14 August 2020 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SCShuntai Chen
Shuntai Chen
YBYanju Bao
Yanju Bao
JXJing Xu
Jing Xu
XZXiwen Zhang
Xiwen Zhang
SHShulin He
Shulin He
宝华宝金 华
宝金 华

29 July 2018 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
QGQiujun Guo
Qiujun Guo
ZJZhichao Jin
Zhichao Jin
YYYuan Yuan
Yuan Yuan
RLRui Liu
Rui Liu
TXTao Xu
Tao Xu
BHBaojin Hua
Baojin Hua
[This corrects the article DOI: 10.1155/2016/9720912.].

15 February 2021 in Research Square
Verified
Preprint
Open access
PDF file
SCShuntai Chen
Shuntai Chen
JHJie He
Jie He
SHShulin He
Shulin He
CLConghuang Li
Conghuang Li
LGLiang Geng
Liang Geng
宝华宝金 华
宝金 华
Background: Small cell lung cancer (SCLC) tends to respond well to the standard treatment of chemotherapy, but disease progression, chemotherapy resistance, and adverse reactions still remain major problems that have long limited its effectiveness. Although Traditional Chinese Medicine (TCM) is wildly applied for patients with SCLC in China, using TCM in the treatment for SCLC is still in the absence of sufficient evidence.Purpose: To evaluate the efficacy and safety of TCM combined with the first lines chemotherapy for SCLC.Method: In this perspective, two-center cohort studies, overall survival (OS), progression free survival (PFS), overall response rate (ORR), and disease control rate (DCR) were compared between patients who received chemotherapy with or without TCM, with adverse events (AEs) also on the list of comparison.Results: When the follow-up ended, 168 patients were included in this study. Compared with patients treated with chemotherapy alone (non-TCM group), those with TCM and chemotherapy (TCM group) had better PFS (adjusted HR 0.552, 95% CI 0.389–0.783, P=0.01), median PFS (11.83 months vs. 8.60 months, P = 0.004), rates of ORR (85.88% vs 75.90% after second cycle treatment, 61.2% vs. 43.4% after fourth cycle treatment), rates of DCR(100% vs 98.80% after second cycle treatment, 95.3% vs. 89.2% after fourth cycle treatment). The number of cases with leukopenia, anorexia, constipation, fatigue, nausea in patients receiving TCM treatment is lower than those in patients not receiving TCM (P < 0.05). There was no difference between the two groups in median OS (23.4 months vs. 20.1 months, P = 0.301). Subgroup analysis showed there was no difference between the two groups in median OS with 34.5 months vs. 22.6 months for LS-SCLC (P=0. 586) and 18.5 months vs. 17.37 months for ES-SCLC (P=0.162). Patients in the TCM group have better median PFS than patients in the non-TCM group for both LS-SCLC and ES-SCLC with 14.73 months vs. 9.2 months (P=0.040) and 9.53 months vs. 7.47 months (P=0.007) respectively.Conclusion: This study indicated that TCM combined with chemotherapy for SCLC may prolong PFS, improve therapeutic effect, reduce the side effects of chemotherapy, but may not be effective in the prolongation of OS. More large-scale and higher quality clinical studies are warranted to support our findings.Clinical registration number: ChiCTR2000040151. (http://www.chictr.org.cn)